Published in J Immunol on June 15, 2008
New insights on adenovirus as vaccine vectors. Mol Ther (2009) 1.90
A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. Vaccine (2008) 1.05
Novel vaccine development strategies for inducing mucosal immunity. Expert Rev Vaccines (2012) 1.04
A novel combined adjuvant for nasal delivery elicits mucosal immunity to influenza in aging. Vaccine (2011) 0.91
The nasal dendritic cell-targeting Flt3 ligand as a safe adjuvant elicits effective protection against fatal pneumococcal pneumonia. Infect Immun (2011) 0.88
TLR2-dependent modulation of dendritic cells by LT-IIa-B5, a novel mucosal adjuvant derived from a type II heat-labile enterotoxin. J Leukoc Biol (2011) 0.87
Cytokines: the future of intranasal vaccine adjuvants. Clin Dev Immunol (2011) 0.87
Oral-nasopharyngeal dendritic cells mediate T cell-independent IgA class switching on B-1 B cells. PLoS One (2011) 0.84
Nasal immunity to staphylococcal toxic shock is controlled by the nasopharynx-associated lymphoid tissue. Clin Vaccine Immunol (2011) 0.83
Enhancement of serum and mucosal immune responses to a Haemophilus influenzae Type B vaccine by intranasal delivery. Clin Vaccine Immunol (2013) 0.81
Mucosal Immunosenescence in the Gastrointestinal Tract: A Mini-Review. Gerontology (2014) 0.80
Phenotype and function of nasal dendritic cells. Mucosal Immunol (2015) 0.78
Intranasal DNA Vaccine for Protection against Respiratory Infectious Diseases: The Delivery Perspectives. Pharmaceutics (2014) 0.78
Potential roles of CCR5(+) CCR6(+) dendritic cells induced by nasal ovalbumin plus Flt3 ligand expressing adenovirus for mucosal IgA responses. PLoS One (2013) 0.77
Adipose-Derived Mesenchymal Stem Cells Restore Impaired Mucosal Immune Responses in Aged Mice. PLoS One (2016) 0.76
Innate endogenous adjuvants prime to desirable immune responses via mucosal routes. Protein Cell (2014) 0.75
Dendritic cells and the control of immunity. Nature (1998) 56.54
A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A (1998) 24.58
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol (2001) 11.07
CX3CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. Science (2005) 8.97
Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. J Exp Med (1998) 6.12
Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc Natl Acad Sci U S A (1999) 5.66
Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med (1996) 5.32
Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3alpha, MIP-3beta, and secondary lymphoid organ chemokine. J Exp Med (2000) 3.43
Differential production of IL-12, IFN-alpha, and IFN-gamma by mouse dendritic cell subsets. J Immunol (2001) 3.39
CCR6 mediates dendritic cell localization, lymphocyte homeostasis, and immune responses in mucosal tissue. Immunity (2000) 3.28
CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol (2006) 3.04
Mouse plasmacytoid cells: long-lived cells, heterogeneous in surface phenotype and function, that differentiate into CD8(+) dendritic cells only after microbial stimulus. J Exp Med (2002) 2.94
The development, maturation, and turnover rate of mouse spleen dendritic cell populations. J Immunol (2000) 2.76
CCR5 provides a signal for microbial induced production of IL-12 by CD8 alpha+ dendritic cells. Nat Immunol (2000) 2.49
Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoietic cells. Cell (1993) 2.40
Distinct populations of dendritic cells are present in the subepithelial dome and T cell regions of the murine Peyer's patch. J Exp Med (1996) 2.38
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Origin and differentiation of dendritic cells. Trends Immunol (2001) 2.04
Hematologic effects of flt3 ligand in vivo in mice. Blood (1996) 2.02
Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol (2000) 1.93
Novel pathways of antigen presentation for the maintenance of memory. Int Immunol (1991) 1.85
STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci U S A (1994) 1.67
Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol Rev (2004) 1.66
Modulating the immune response with dendritic cells and their growth factors. Trends Immunol (2001) 1.66
CCL9 is secreted by the follicle-associated epithelium and recruits dome region Peyer's patch CD11b+ dendritic cells. J Immunol (2003) 1.54
Intratracheal gene delivery with adenoviral vector induces elevated systemic IgG and mucosal IgA antibodies to adenovirus and beta-galactosidase. Hum Gene Ther (1995) 1.48
Cloning of the human homologue of the murine flt3 ligand: a growth factor for early hematopoietic progenitor cells. Blood (1994) 1.41
CCR6 expression distinguishes mouse myeloid and lymphoid dendritic cell subsets: demonstration using a CCR6 EGFP knock-in mouse. Eur J Immunol (2002) 1.38
Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid. J Clin Invest (2005) 1.35
Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med (1997) 1.35
Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol (2005) 1.31
Active MAC-1 (CD11b/CD18) on DCs inhibits full T-cell activation. Blood (2006) 1.23
Peyer's patches are required for oral tolerance to proteins. Proc Natl Acad Sci U S A (2001) 1.21
Modulating dendritic cells to optimize mucosal immunization protocols. J Immunol (1999) 1.19
Chemokine receptors and leukocyte trafficking in the mucosal immune system. Immunol Res (2004) 1.15
Protective mucosal immunity in aging is associated with functional CD4+ T cells in nasopharyngeal-associated lymphoreticular tissue. J Immunol (2003) 1.09
Flt3 ligand preferentially increases the number of functionally active myeloid dendritic cells in the lungs of mice. J Immunol (2004) 1.09
Nasal Flt3 ligand cDNA elicits CD11c+CD8+ dendritic cells for enhanced mucosal immunity. J Immunol (2004) 1.06
Dendritic cell-mediated induction of mucosal cytotoxic responses following intravaginal immunization with the nontoxic B subunit of cholera toxin. J Immunol (2006) 1.05
Flt3 ligand-treated neonatal mice have increased innate immunity against intracellular pathogens and efficiently control virus infections. J Exp Med (2003) 1.05
CD8alpha-11b+ dendritic cells but not CD8alpha+ dendritic cells mediate cross-tolerance toward intestinal antigens. Blood (2005) 1.04
Impaired lung dendritic cell activation in CCR2 knockout mice. Am J Pathol (2004) 1.04
A nontoxic chimeric enterotoxin adjuvant induces protective immunity in both mucosal and systemic compartments with reduced IgE antibodies. J Infect Dis (2002) 1.03
Adenoviral gene delivery elicits distinct pulmonary-associated T helper cell responses to the vector and to its transgene. J Immunol (1997) 0.99
A second generation of double mutant cholera toxin adjuvants: enhanced immunity without intracellular trafficking. J Immunol (2006) 0.96
Antigen-induced, tolerogenic CD11c+,CD11b+ dendritic cells are abundant in Peyer's patches during the induction of oral tolerance to type II collagen and suppress experimental collagen-induced arthritis. Arthritis Rheum (2006) 0.93
Spleen but not tumor infiltration by dendritic and T cells is increased by intravenous adenovirus-Flt3 ligand injection. Cancer Gene Ther (2007) 0.93
CD8alpha+ mouse spleen dendritic cells do not originate from the CD8alpha- dendritic cell subset. Blood (2003) 0.92
Mucosal vaccine targeting improves onset of mucosal and systemic immunity to botulinum neurotoxin A. J Immunol (2006) 0.91
How do DCs interact with intestinal antigens? Trends Immunol (2005) 0.90
FLT3 ligand administration inhibits tumor growth in murine melanoma and lymphoma. Cancer Res (1998) 0.89
Midkine promoter-based adenoviral vector gene delivery for pediatric solid tumors. Cancer Res (2000) 0.88
Comparison of the hematopoietic activity of flt-3 ligand and granulocyte-macrophage colony-stimulating factor acting alone or in combination. J Hematother Stem Cell Res (2000) 0.83
The haemopoietic growth factor, Flt3L, alters the immune response induced by transcutaneous immunization. Immunology (2002) 0.80
Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine. Int J Immunopharmacol (2000) 0.78
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. Nat Med (2003) 7.35
Corneal avascularity is due to soluble VEGF receptor-1. Nature (2006) 4.77
Engineering targeted viral vectors for gene therapy. Nat Rev Genet (2007) 3.69
A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota. Proc Natl Acad Sci U S A (2009) 2.77
Radiation-induced cell signaling: inside-out and outside-in. Mol Cancer Ther (2007) 2.56
Mechanism of autophagy to apoptosis switch triggered in prostate cancer cells by antitumor cytokine melanoma differentiation-associated gene 7/interleukin-24. Cancer Res (2010) 2.13
MDA-7 regulates cell growth and radiosensitivity in vitro of primary (non-established) human glioma cells. Cancer Biol Ther (2004) 1.90
Mesenchymal progenitor cells as cellular vehicles for delivery of oncolytic adenoviruses. Mol Cancer Ther (2006) 1.88
Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst (2003) 1.86
A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther (2003) 1.86
Determination of smoking and obesity as periodontitis risks using the classification and regression tree method. J Periodontol (2005) 1.85
Current issues and future directions of oncolytic adenoviruses. Mol Ther (2009) 1.80
Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. Cancer Res (2002) 1.74
Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res (2002) 1.74
Indigenous opportunistic bacteria inhabit mammalian gut-associated lymphoid tissues and share a mucosal antibody-mediated symbiosis. Proc Natl Acad Sci U S A (2010) 1.67
Enhanced adenovirus infection of melanoma cells by fiber-modification: incorporation of RGD peptide or Ad5/3 chimerism. Cancer Biol Ther (2003) 1.66
Self-assembling nanoclusters in living systems: application for integrated photothermal nanodiagnostics and nanotherapy. Nanomedicine (2005) 1.66
mda-7/IL-24, a novel cancer selective apoptosis inducing cytokine gene: from the laboratory into the clinic. Cancer Biol Ther (2003) 1.63
In vivo molecular chemotherapy and noninvasive imaging with an infectivity-enhanced adenovirus. J Natl Cancer Inst (2002) 1.61
Covalently linked Au nanoparticles to a viral vector: potential for combined photothermal and gene cancer therapy. Nano Lett (2006) 1.61
Generation of a transplantable erythropoietin-producer derived from human mesenchymal stem cells. Transplantation (2008) 1.58
A dilemma for mucosal vaccination: efficacy versus toxicity using enterotoxin-based adjuvants. Vaccine (2002) 1.58
mda-7/IL-24: multifunctional cancer-specific apoptosis-inducing cytokine. Pharmacol Ther (2006) 1.56
Vorinostat and sorafenib synergistically kill tumor cells via FLIP suppression and CD95 activation. Clin Cancer Res (2008) 1.55
Association between involuntary smoking and salivary markers related to periodontitis: a 2-year longitudinal study. J Periodontol (2008) 1.54
OSU-03012 stimulates PKR-like endoplasmic reticulum-dependent increases in 70-kDa heat shock protein expression, attenuating its lethal actions in transformed cells. Mol Pharmacol (2008) 1.52
Acute compartment syndrome of the forearm that occurred after transradial intervention and was not caused by bleeding or hematoma formation. Catheter Cardiovasc Interv (2010) 1.52
Survivin-driven and fiber-modified oncolytic adenovirus exhibits potent antitumor activity in established intracranial glioma. Hum Gene Ther (2007) 1.48
Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Mol Cancer Ther (2008) 1.48
Streptococcus gordonii utilizes several distinct gene functions to recruit Porphyromonas gingivalis into a mixed community. Mol Microbiol (2006) 1.47
Relationship between sleep apnea and thyroid function. Sleep Breath (2014) 1.44
A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin Cancer Res (2004) 1.44
Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther (2003) 1.43
Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene (2005) 1.43
Relationships among nasal obstruction, daytime sleepiness, and quality of life. Laryngoscope (2006) 1.41
Mesenchymal stem cells as a vehicle for targeted delivery of CRAds to lung metastases of breast carcinoma. Breast Cancer Res Treat (2007) 1.41
Multiple Beneficial Effects of Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension. Circ J (2016) 1.40
Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs (2011) 1.39
Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med (2006) 1.36
Construction and characterization of adenovirus serotype 5 packaged by serotype 3 hexon. J Virol (2002) 1.35
Glyceraldehyde-3-phosphate dehydrogenase of Streptococcus oralis functions as a coadhesin for Porphyromonas gingivalis major fimbriae. Infect Immun (2004) 1.35
Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J Virol (2002) 1.35
mda-7/IL-24, novel anticancer cytokine: focus on bystander antitumor, radiosensitization and antiangiogenic properties and overview of the phase I clinical experience (Review). Int J Oncol (2007) 1.34
Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J Immunol (2003) 1.34
Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J Virol (2002) 1.33
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicity. Proc Natl Acad Sci U S A (2011) 1.31
Eradication of therapy-resistant human prostate tumors using a cancer terminator virus. Cancer Res (2007) 1.31
Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res (2002) 1.30
mda-7/IL-24: a unique member of the IL-10 gene family promoting cancer-targeted toxicity. Cytokine Growth Factor Rev (2010) 1.30
Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther (2002) 1.28
Infectivity enhanced, cyclooxygenase-2 promoter-based conditionally replicative adenovirus for pancreatic cancer. Gastroenterology (2003) 1.28
Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology (2004) 1.27
Presence and severity of Chlamydia pneumoniae and Cytomegalovirus infection in coronary plaques are associated with acute coronary syndromes. Int Heart J (2006) 1.26
Historical perspective and recent insights into our understanding of the molecular and biochemical basis of the antitumor properties of mda-7/IL-24. Cancer Biol Ther (2009) 1.25
P. gingivalis accelerates gingival epithelial cell progression through the cell cycle. Microbes Infect (2007) 1.23
PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Res (2010) 1.23
Structure and uncoating of immature adenovirus. J Mol Biol (2009) 1.23
IFN-gamma-inducible chemokines enhance adaptive immunity and colitis. J Interferon Cytokine Res (2003) 1.21
The human survivin promoter: a novel transcriptional targeting strategy for treatment of glioma. J Neurosurg (2006) 1.21
A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res (2010) 1.21
MIP-1alpha and MIP-1beta differentially mediate mucosal and systemic adaptive immunity. Blood (2002) 1.21
Distinct roles of long/short fimbriae and gingipains in homotypic biofilm development by Porphyromonas gingivalis. BMC Microbiol (2009) 1.20
Interleukin-6 induces both cell growth and VEGF production in malignant mesotheliomas. Int J Cancer (2006) 1.19
Identification of sites in adenovirus hexon for foreign peptide incorporation. J Virol (2005) 1.19
Pneumococcal carriage results in ganglioside-mediated olfactory tissue infection. Proc Natl Acad Sci U S A (2003) 1.19
Fluorescently labeled adenovirus with pIX-EGFP for vector detection. Mol Imaging (2004) 1.18
New prospective payment system in Japan. Am J Health Syst Pharm (2005) 1.18
Current developments in adenovirus-based cancer gene therapy. Future Oncol (2006) 1.18
MDA-7/IL-24 plus radiation enhance survival in animals with intracranial primary human GBM tumors. Cancer Biol Ther (2008) 1.18
Genetically targeted adenovirus vector directed to CD40-expressing cells. J Virol (2003) 1.18
Mechanism by which Mcl-1 regulates cancer-specific apoptosis triggered by mda-7/IL-24, an IL-10-related cytokine. Cancer Res (2010) 1.18
Involvement of minor components associated with the FimA fimbriae of Porphyromonas gingivalis in adhesive functions. Microbiology (2007) 1.17
Somatostatinoma of the papilla of Vater with multiple gastrointestinal stromal tumors in a patient with von Recklinghausen's disease. J Gastroenterol (2002) 1.17
The presence of the adenovirus E3 region improves the oncolytic potency of conditionally replicative adenoviruses. Clin Cancer Res (2002) 1.17
Double modification of adenovirus fiber with RGD and polylysine motifs improves coxsackievirus-adenovirus receptor-independent gene transfer efficiency. Hum Gene Ther (2002) 1.16
A Porphyromonas gingivalis tyrosine phosphatase is a multifunctional regulator of virulence attributes. Mol Microbiol (2008) 1.16
HIV infection: first battle decides the war. Trends Immunol (2006) 1.15
Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun (2005) 1.15
Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res (2002) 1.15
Delta-24 increases the expression and activity of topoisomerase I and enhances the antiglioma effect of irinotecan. Clin Cancer Res (2006) 1.15
Eradication of therapy-resistant human prostate tumors using an ultrasound-guided site-specific cancer terminator virus delivery approach. Mol Ther (2009) 1.14
Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res (2002) 1.14
Promotion of incisional wound repair by human mesenchymal stem cell transplantation. Exp Dermatol (2008) 1.14
Intravenous delivery of adenovirus-mediated soluble FLT-1 results in liver toxicity. Clin Cancer Res (2003) 1.14
Safety and immunogenicity of a DNA vaccine encoding carcinoembryonic antigen and hepatitis B surface antigen in colorectal carcinoma patients. Clin Cancer Res (2002) 1.13
Genetic incorporation of a herpes simplex virus type 1 thymidine kinase and firefly luciferase fusion into the adenovirus protein IX for functional display on the virion. Mol Imaging (2006) 1.13
Contrasting effects of human, canine, and hybrid adenovirus vectors on the phenotypical and functional maturation of human dendritic cells: implications for clinical efficacy. J Virol (2007) 1.13
Three-dimensional structure of canine adenovirus serotype 2 capsid. J Virol (2008) 1.13
Triple-targeted oncolytic adenoviruses featuring the cox2 promoter, E1A transcomplementation, and serotype chimerism for enhanced selectivity for ovarian cancer cells. Mol Ther (2006) 1.12
Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy. Drug Resist Updat (2009) 1.12